NCT01442987

Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia

Efficacy and Safety of Coadministered Irbesartan and Atorvastatin in Patients With Hypertension and Hyperlipidemia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 230 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 19 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate efficacy and safety of coadministered Irbesartan and Atorvastatin in patients with hypertension and hyperlipidemia.

Conditions

• Hypertension
• Hyperlipidemia

Interventions

Type	Name	Description
DRUG	Irbesartan/Atorvastatin A	once daily, P.O. 8week
DRUG	Irbesartan	once daily, P.O. 8week
DRUG	Atorvastatin A	once daily, P.O. 8week
DRUG	Placebo	once daily, P.O. 8week
DRUG	Irbesartan/Atorvastatin B	once daily, P.O. 8week
DRUG	Atorvastatin B	once daily, P.O. 8week

Timeline

• Start date: 2011-05-01
• Primary completion: 2013-04-01
• Completion: 2013-05-01
• First posted: 2011-09-29
• Last updated: 2013-08-13

Locations

1 site across 1 country: South Korea